NCT04172090

Brief Summary

Physical inactivity is a significant predictor of major non-communicable diseases such as type 2 diabetes (7%), cardiovascular disease (6%), musculoskeletal disorders and some cancers, and has been proposed to be the 4th leading cause of death worldwide. Reduced physical activity leads to an impaired function of the hormone insulin and increased adiposity. Thus, the elimination of physical inactivity would remove between 6% and 10% of the major non-communicable diseases and increase life expectancy. The aim of the study is to investigate the effects of a short-term (2-day) period of reduced physical activity, with and without a proportional decrease in energy intake, on the action of insulin to regulate blood sugar fluctuations, appetite, and cardiovascular parameters (heart rate, cardiac output, stroke volume, blood flow, arterial blood pressure, peripheral vascular resistance) in response to food ingestion.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
8

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2017

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 20, 2017

Completed
2.1 years until next milestone

First Submitted

Initial submission to the registry

November 19, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 21, 2019

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 13, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 13, 2020

Completed
Last Updated

March 30, 2020

Status Verified

November 1, 2019

Enrollment Period

2.4 years

First QC Date

November 19, 2019

Last Update Submit

March 27, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • The incremental area under curve for Insulin

    The incremental area under curve for Insulin will be calculated using samples collected at 20 minute intervals between baseline and three hours

    Over three hours from baseline

Secondary Outcomes (1)

  • The incremental area under curve for arterialized whole blood glucose

    Over four hours from baseline

Other Outcomes (7)

  • The incremental area under curve for free fatty acids

    Over three hours from baseline

  • The incremental area under curve for Triglycerides

    Over three hours from baseline

  • The incremental area under curve for Ghrelin

    Over four hours from baseline

  • +4 more other outcomes

Study Arms (3)

Control

OTHER

2 consecutive days of standardised daily levels of moderate physical activity (PAL=1.85 reflecting their habitual levels), and matched energy (food) intake

Other: Control

SIT+E

EXPERIMENTAL

2 consecutive days of reduced physical activity induced by prolonged periods of sitting (PAL=1.4) whilst maintaining the level of food intake prescribed in the Control trial, thus creating a positive energy balance

Other: SIT+E

SIT=E

EXPERIMENTAL

2 consecutive days of reduced physical activity induced by prolonged periods of sitting (PAL=1.4) whilst reducing food intake to match the reduction in energy expenditure induced by inactivity, thus maintaining energy balance

Other: SIT=E

Interventions

ControlOTHER

Normal physical activity and standard energy intake

Control
SIT=EOTHER

Reduced physical activity and reduced energy intake

SIT=E

Eligibility Criteria

Age18 Years - 35 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Non-smoking
  • Males and females
  • Age (18-35 years old)
  • Body mass index (BMI) of 18-27 kg/m2
  • Waist circumference \<94cm for males and \<80cm for females
  • Ability to give informed consent

You may not qualify if:

  • Smoking
  • Any metabolic (e.g. diabetes), endocrine (e.g. hyperthyroidism) or cardiovascular (e.g. heart or blood) abnormalities including hypertension or heart failure
  • Clinically significant abnormalities on screening including ECG abnormalities
  • Taking routine medication that may alter cardiovascular function and blood flow (e.g. blood pressure-lowering drugs or drugs that cause hypertension)
  • Well trained individuals with PAL\>2.00; on an energy-restricted diet or seeking to lose weight
  • High alcohol consumption (\<3-4 units/d for men; \<2-3 units/d for women)
  • Females who are pregnant or lactating; self-reported allergy, intolerance or strong dislike of foods or drinks to be offered for the test breakfast, pasta meal or during the intervention period
  • Beck Depression Inventory score \>10 and Eating Attitudes Test (EAT-26) score \>20 as self-reported markers of symptoms and concerns characteristic of depression and eating disorders, respectively.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Nottingham

Nottingham, United Kingdom

Location

MeSH Terms

Conditions

Sedentary Behavior

Condition Hierarchy (Ancestors)

Behavior

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 19, 2019

First Posted

November 21, 2019

Study Start

October 20, 2017

Primary Completion

March 13, 2020

Study Completion

March 13, 2020

Last Updated

March 30, 2020

Record last verified: 2019-11

Data Sharing

IPD Sharing
Will not share

only anonymised individual personal data will be shared, upon specific request from other researchers, for example, in order to undertake a meta analysis

Locations